PDCD1 and metastatic melanoma: This nationwide trial aims to determine the safety and efficacy of early discontinuation of maintenance treatment with anti-PD-1 upon achieving a (confirmed) response for patients with irresectable stage III or metastatic melanoma who are treated with the combination therapy of ipilimumab and nivolumab.